View the latest Magenta Therapeutics Inc. (MGTA) stock price, news, historical charts, analyst ratings and financial information from WSJ. What is MGTA stock forecast (i.e., prediction)? View Magenta Therapeutics' (NASDAQ:MGTA) earnings history, next earnings date and earnings forecasts from top-rated Wall Street analysts at MarketBeat. Our stock price predictions cover a period of 3 months. $12.02 -0.7 -5.7% Last Trade - 9:00pm. In the included table, only the relevant stocks have been included. Magenta Therapeutics Inc reported $0 in Sales Revenues for its third fiscal quarter of 2020. MGTA Stock Predictions. See Magenta Therapeutics, Inc. (MGTA) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. S&P 500 4,183.18. Co.'s third ADC-based conditioning program, C300, targets T cells, a type of immune cell. The prediction is based on 5 analyst estimates. We cover the US equity market. Toggle navigation. Find real-time ADT - ADT Inc stock quotes, company profile, news and forecasts from CNN Business. The MGTA stock forecast is provided by MarketClub with their Trade Triangle system. We cover the US equity market. The company's largest shareholder is Third Rock Ventures, LLC, with ownership of 16%. Stocks: 15 20 minute delay (Cboe BZX is real-time), ET. Stock Price Forecast The 4 analysts offering 12-month price forecasts for Magenta Therapeutics Inc have a median target of 15.50, with a high estimate of 22.00 and a low estimate of 13.00. According to present data ADT's ADT shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists). Magenta Therapeutics, Inc. Common Stock (MGTA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Since the short-term average is above the long-term average there is a general buy signal in the ETF giving a positive forecast for the stock. Find out now. View the latest ETF prices and news for better ETF investing. Should I buy MGTA stock? Magenta Therapeutics Inc. analyst ratings, historical stock prices, earnings estimates & actuals. Find the latest Earnings Report Date for Magenta Therapeutics, Inc. Common Stock (MGTA) at Nasdaq.com. Magenta Therapeutics Inc (MGTA:NMQ) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. Futures and Forex: 10 or 15 minute delay, CT. Market Data powered by Barchart Solutions. Magenta Therapeutics price history, MGTA 1 day chart with daily, weekly, monthly prices and market capitalizations. Our stock price predictions cover a period of 3 months. The stock has traded between $6.57 and $7.00 so far today. 3 Forgotten Growth Stocks … It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Close. A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Wall Street Stock Market & Finance report, prediction for the future: You'll find the ADT share forecasts, stock quote and buy / sell signals below. MAGENTA THERAPEUTICS, INC. earnings per share revisions and analysts forecast | Nasdaq: MGTA | Nasdaq View Magenta Therapeutics' (NASDAQ:MGTA) earnings history, next earnings date and earnings forecasts from top-rated Wall Street analysts at MarketBeat. MGK | A complete Vanguard Mega Cap Growth ETF exchange traded fund overview by MarketWatch. A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. (Updated on April 20, 2021) Sell candidate since 2021-04-05 Loss -16.30% PDF . Volume today is below average. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. Home ; Forecast . Hedge funds don't have many shares in Magenta Therapeutics. Note that the top 10 stocks in the 1-month forecast may be different than those in the 1-year forecast. So far 93,771 shares have traded compared to average volume of 174,639 shares. Adventurous. The 12-month stock price forecast is 18.33, which is an increase of 57.75% from the latest price. Find the latest Magenta Therapeutics, Inc. (MGTA) stock quote, history, news and other vital information to help you with your stock trading and investing. Signals & Forecast. We use big data and artificial intelligence to forecast the stock price of Magenta Therapeutics Inc - MGTA. My model is forecasting electric car sales to move from 2.2% market share (~2.1 m sales) as of end 2018, to 20% by end 2025, for a 9x increase in just seven years. The 12-month stock price forecast is 18.33, which is an increase of 57.75% from the latest price. Stronger technical forecast for Molecular Templates Inc stock price after Tuesday trading. 60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). Co.'s main conditioning product candidate, MGTA-117, is designed to specifically remove disease-causing hematopoietic stem cells and genetically mutated cells. Fundamental data provided by Zacks and Morningstar. Magenta Therapeutics Inc Stock Price Forecast, "MGTA" Predictons for2021 Each day, subscribers receive forecasts for six different time horizons. MGTA Technical Analysis. Click here for a FREE analysis on MGTA. Algorithmic Stock Forecast: The table on the left is a stock forecast produced by I Know First’s algorithm. Dividend Growth Stocks: 25 Aristocrats 10 Dividend Bargains You Can Buy Cheaper Than Insiders Did. The Vanguard Mega Cap Growth Index Fund ETF holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. We use big data and artificial intelligence to forecast the stock price of Magenta Therapeutics Inc - MGTA. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock. × . MGTA - Magenta Therapeutics Inc Share Price. The ADT Inc. stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. The Molecular Templates Inc stock price fell by -3.98% on the last day (Tuesday, 20th Apr 2021) from $8.29 to $7.96.During the day the stock fluctuated 6.43% from a day low at $7.93 to a day high of $8.44. The median estimate represents a +43.65% increase from the last price of 10.79. Magenta Therapeutics Inc (MGTA) stock is trading at $6.69 as of 11:10 AM on Monday, Nov 9, an increase of $0.39, or 6.19% from the previous closing price of $6.30. 3. The low price target for MGTA is $13.00, while the high price target is $22.00. Volume reflects consolidated markets. As of 2021 April 17, Saturday current price of MGTA stock is 10.940$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception).. Magenta Therapeutics stock price as been showing a rising tendency so we believe that similar market segments were very popular in the given time frame. Based on MGTA analyst price targets, MGTA stock forecast is $16.50 (for a year from now). That means the average analyst price target for MGTA stock is $16.50. Here Are 3 Hot Stocks to Buy Before 2021 Sirius XM, fuboTV, and Novavax have the right stuff to reward risk-tolerant growth investors in the year … QQQ 339.00. Signals & Forecast. NasdaqGM:MGTA Earnings and Revenue Growth March 17th 2021. The following MGTA technical analysis is based on short term price movement and trend analysis. Magenta Therapeutics Inc reported $0 in Debt for its fourth fiscal quarter of 2020. MGTA updated stock price target summary. Meanwhile, note that the median MGTA forecast price target ... Get the latest Zacks research report on MGTA — FREE. Sector Healthcare RiskRating. NASDAQ:MGTA - Magenta Therapeutics Stock Price Target and Predictions. DOW 33,820.38. About the Magenta Therapeutics, Inc. stock forecast. According to 5 analysts, the average rating for MGTA stock is "Strong Buy." In comparison, the second and third largest shareholders hold about 9.5% and 8.7% of the stock.